Lesogor, Anastasia

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 564

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 328

Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)

Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., et al. (2025) · American Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 169

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright, R. S., Raal, F. J., Koenig, W., Landmesser, U., Leiter, L. A., Vikarunnessa, S., Lesogor, A., Maheux, P., Talloczy, Z., Zang, X., et al. (2024) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 102

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Raal, F., Durst, R., Bi, R., Talloczy, Z., Maheux, P., Lesogor, A., Kastelein, J. J. P., & on behalf of the ORION-5 Study Investigators (2024) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 96

Efficacy and Safety of Inclisiran in Asian Patients

Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 31

Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15

Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 26

Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD

Taub, P. R., Gutierrez, A., Wewers, D., Garcia Cantu, E., Cao, H., Deck, C., Lesogor, A., Ott, D., Mena-Madrazo, J., Zang, X., et al. (2025) · JACC

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 25